Skip to content
2000
Volume 33, Issue 2
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Introduction

ZNF280A, a pivotal member of the zinc finger protein family, is significantly involved in vital cellular functions including cell proliferation, programmed cell death, cellular invasion, metastasis, and resistance to therapeutic drugs across various malignancies. However, its comprehensive role in pan-cancer has not been thoroughly investigated.

Methods

This research aims to elucidate the oncogenic and immunological functions of ZNF280A across different types of cancer. We conducted an extensive analysis of ZNF280A expression levels, prognostic significance, functional pathways, methylation status, and interactions with immune cells, while also examining immune infiltration patterns and responses to immunotherapy using diverse databases.

Results

Our findings reveal that ZNF280A expression is significantly upregulated in numerous cancers, correlating with adverse patient prognosis. This association appears to be linked to its involvement in key cancer-related pathways, including the Ras signaling pathway, and its correlation with ZNF280A methylation levels, microsatellite instability (MSI), tumor mutational burden (TMB), and the dynamics of immune cells. Notably, ZNF280A seems to undermine anti-tumor immunity and the effectiveness of immunotherapeutic approaches by promoting the infiltration of immune cells and compromising the functionality of cytotoxic T lymphocytes.

Conclusion

These findings suggest that ZNF280A holds promise as a valuable indicator for forecasting patient outcomes and assessing the effectiveness of immunotherapy, thereby opening avenues for further exploration into targeted therapeutic approaches.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673359029250316111019
2025-04-07
2026-02-28

  • From This Site

    /content/journals/cmc/10.2174/0109298673359029250316111019
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SiegelR.L. MillerK.D. WagleN.S. JemalA. Cancer statistics, 2023.CA Cancer J. Clin.2023731174810.3322/caac.2176336633525
     [Google Scholar]
  2. LiX. WangY. LiX. KongL. DíezJ.J. WangH. ZhangD. A comprehensive pan-cancer analysis revealing SPAG6 as a novel diagnostic, prognostic and immunological biomarker in tumor.Gland Surg.2024136999101510.21037/gs‑24‑15739015705
     [Google Scholar]
  3. ZebleyC.C. ZehnD. GottschalkS. ChiH. T cell dysfunction and therapeutic intervention in cancer.Nat. Immunol.20242581344135410.1038/s41590‑024‑01896‑939025962
     [Google Scholar]
  4. KamaliyanZ. ClarkeT.L. Zinc finger proteins: Guardians of genome stability.Front. Cell Dev. Biol.202412144878910.3389/fcell.2024.144878939119040
     [Google Scholar]
  5. PadjasekM. KocyłaA. KluskaK. KerberO. TranJ.B. KrężelA. Structural zinc binding sites shaped for greater works: Structure-function relations in classical zinc finger, hook and clasp domains.J. Inorg. Biochem.202020411095510.1016/j.jinorgbio.2019.11095531841759
     [Google Scholar]
  6. CassandriM. SmirnovA. NovelliF. PitolliC. AgostiniM. MalewiczM. MelinoG. RaschellàG. Zinc-finger proteins in health and disease.Cell Death Discov.2017311707110.1038/cddiscovery.2017.7129152378
     [Google Scholar]
  7. ZhangD. LiangP. XiaB. WuJ. HuX. Comprehensive pan-cancer analysis of ZNF337 as a potential diagnostic, immunological, and prognostic biomarker.BMC Cancer202424198710.1186/s12885‑024‑12703‑x39123194
     [Google Scholar]
  8. HeL. WangX. ChenP. DuC. LiJ. Knockdown of ZNF280A inhibits cell proliferation and promotes cell apoptosis of bladder cancer.Histol. Histopathol.202439336737937345848
     [Google Scholar]
  9. WangX. SunD. TaiJ. ChenS. HongS. WangL. ZNF280A promotes proliferation and tumorigenicity via inactivating the hippo-signaling pathway in colorectal cancer.Mol. Ther. Oncolytics20191220421310.1016/j.omto.2019.01.00230847384
     [Google Scholar]
  10. LiuH. QinY. ZhouN. MaD. WangY. ZNF280A promotes lung adenocarcinoma development by regulating the expression of EIF3C.Cell Death Dis.20211213910.1038/s41419‑020‑03309‑933414445
     [Google Scholar]
  11. ZhengX. YangL. ShenX. PanJ. ChenY. ChenJ. WangH. MengJ. ChenZ. XieS. LiY. ZhuB. ZhuW. QinL. LuL. Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma.J. Immunother. Cancer2024128e00964210.1136/jitc‑2024‑00964239174053
     [Google Scholar]
  12. ChenX. WangD. LiuJ. QiuJ. ZhouJ. YingJ. ShiY. WangZ. LouH. CuiJ. ZhangJ. LiuY. ZhaoF. PanL. ZhaoJ. ZhuD. ChenS. LiX. LiX. ZhuL. ShaoY. ShuY. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.J. Immunother. Cancer2021911e00321410.1136/jitc‑2021‑00321434795005
     [Google Scholar]
  13. LuchiniC. BibeauF. LigtenbergM.J.L. SinghN. NottegarA. BosseT. MillerR. RiazN. DouillardJ.Y. AndreF. ScarpaA. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach.Ann. Oncol.20193081232124310.1093/annonc/mdz11631056702
     [Google Scholar]
  14. FerritoN. Báez-FloresJ. Rodríguez-MartínM. Sastre-RodríguezJ. CoppolaA. Isidoro-GarcíaM. Prieto- MatosP. LacalJ. Biomarker landscape in RASopathies.Int. J. Mol. Sci.20242516856310.3390/ijms2516856339201250
     [Google Scholar]
  15. GaoY. ZhengH. Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review.Crit. Rev. Oncol. Hematol.202420310448410.1016/j.critrevonc.2024.10448439197669
     [Google Scholar]
  16. GargP. RamisettyS.K. Raghu SubbalakshmiA. KrishnaB.M. PareekS. MohantyA. KulkarniP. HorneD. SalgiaR. SinghalS.S. Gynecological cancer tumor microenvironment: Unveiling cellular complexity and therapeutic potential.Biochem. Pharmacol.202422911649810.1016/j.bcp.2024.11649839159874
     [Google Scholar]
  17. ChenC. LiuX. ChangC.Y. WangH.Y. WangR.F. The interplay between T cells and cancer: The basis of immunotherapy.Genes2023145100810.3390/genes1405100837239368
     [Google Scholar]
  18. TongW. WangT. BaiY. YangX. HanP. ZhuL. ZhangY. ShenZ. Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment.J. Transl. Med.202422184010.1186/s12967‑024‑05613‑w39267037
     [Google Scholar]
  19. Reina-CamposM. ScharpingN.E. GoldrathA.W. CD8+ T cell metabolism in infection and cancer.Nat. Rev. Immunol.2021211171873810.1038/s41577‑021‑00537‑833981085
     [Google Scholar]
  20. BuckM.D. SowellR.T. KaechS.M. PearceE.L. Metabolic instruction of immunity.Cell2017169457058610.1016/j.cell.2017.04.00428475890
     [Google Scholar]
  21. ZhengC. SnowB.E. EliaA.J. NechanitzkyR. Dominguez-BrauerC. LiuS. TongY. CoxM.A. FocacciaE. WakehamA.C. HaightJ. TobinC. HodgsonK. GillK.T. MaW. BergerT. HeikenwälderM. SaundersM.E. FortinJ. LeungS.Y. MakT.W. Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma.Nat. Can.20234101437145410.1038/s43018‑023‑00624‑w37640929
     [Google Scholar]
  22. van der LeunA.M. ThommenD.S. SchumacherT.N. CD8+ T cell states in human cancer: Insights from single-cell analysis.Nat. Rev. Cancer202020421823210.1038/s41568‑019‑0235‑432024970
     [Google Scholar]
  23. BraunD.A. HouY. BakounyZ. FicialM. Sant’ AngeloM. FormanJ. Ross-MacdonaldP. BergerA.C. JegedeO.A. ElaginaL. SteinharterJ. SunM. Wind-RotoloM. PignonJ.C. CherniackA.D. LichtensteinL. NeubergD. CatalanoP. FreemanG.J. SharpeA.H. McDermottD.F. Van AllenE.M. SignorettiS. WuC.J. ShuklaS.A. ChoueiriT.K. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.Nat. Med.202026690991810.1038/s41591‑020‑0839‑y32472114
     [Google Scholar]
  24. PengY.L. XiongL.B. ZhouZ.H. NingK. LiZ. WuZ.S. DengM.H. WeiW.S. WangN. ZouX.P. HeZ.S. HuangJ.W. LuoJ.H. LiuJ.Y. JiaN. CaoY. HanH. GuoS.J. DongP. YuC.P. ZhouF.J. ZhangZ.L. Single-cell transcriptomics reveals a low CD8 + T cell infiltrating state mediated by fibroblasts in recurrent renal cell carcinoma.J. Immunother. Cancer2022102e00420610.1136/jitc‑2021‑00420635121646
     [Google Scholar]
  25. SunL. LinY. WangG. ZhangL. HuL. LuZ. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer.Biosci. Rep.2021411BSR2020311510.1042/BSR2020311533439969
     [Google Scholar]
  26. HuQ. YueB. LiuJ. GaoY. HuangX. HuY. Pan- cancer bioinformatics indicates zinc finger protein 207 is a promising prognostic biomarker and immunotherapeutic target.J. Leukoc. Biol.20241171qiae14710.1093/jleuko/qiae14738970506
     [Google Scholar]
  27. GeL.P. JinX. MaD. WangZ.Y. LiuC.L. ZhouC.Z. ZhaoS. YuT.J. LiuX.Y. DiG.H. ShaoZ.M. JiangY.Z. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.Cell Res.2024341587510.1038/s41422‑023‑00909‑w38168642
     [Google Scholar]
  28. NiR. HuZ. TaoR. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer.Biomed. Pharmacother.202417911743010.1016/j.biopha.2024.11743039260322
     [Google Scholar]
  29. RayfordA. GärtnerF. RamnefjellM.P. LorensJ.B. MicklemD.R. AanerudM. EngelsenA.S.T. AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.Front. Immunol.202415144400710.3389/fimmu.2024.144400739238637
     [Google Scholar]
  30. AmbrosiniM. TougeronD. ModestD. GuimbaudR. KopetzS. DecraeckerM. KimS. CoutzacC. PerkinsG. AlouaniE. MarmorinoF. PernotS. SinicropeF.A. ElezE. ParentP. CremoliniC. PietrantonioF. LonardiS. GalloisC. TaiebJ. BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.Eur. J. Cancer202421011429010.1016/j.ejca.2024.11429039216175
     [Google Scholar]
  31. LiuM. LiuQ. HuK. DongY. SunX. ZouZ. JiD. LiuT. YuY. Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment.Crit. Rev. Oncol. Hematol.202420410449710.1016/j.critrevonc.2024.10449739245296
     [Google Scholar]
  32. RizviH. Sanchez-VegaF. LaK. ChatilaW. JonssonP. HalpennyD. PlodkowskiA. LongN. SauterJ.L. RekhtmanN. HollmannT. SchalperK.A. GainorJ.F. ShenR. NiA. ArbourK.C. MerghoubT. WolchokJ. SnyderA. ChaftJ.E. KrisM.G. RudinC.M. SocciN.D. BergerM.F. TaylorB.S. ZehirA. SolitD.B. ArcilaM.E. LadanyiM. RielyG.J. SchultzN. HellmannM.D. Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing.J. Clin. Oncol.201836763364110.1200/JCO.2017.75.338429337640
     [Google Scholar]
  33. BudcziesJ. KazdalD. MenzelM. BeckS. KluckK. AltbürgerC. SchwabC. AllgäuerM. AhadovaA. KloorM. SchirmacherP. PetersS. KrämerA. ChristopoulosP. StenzingerA. Tumour mutational burden: Clinical utility, challenges and emerging improvements.Nat. Rev. Clin. Oncol.2024211072574210.1038/s41571‑024‑00932‑939192001
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673359029250316111019
Loading
Mapping the Multifaceted Roles of ZNF280A: Insights into Prognosis, Immunity, and Function Across Pan-Cancer
Curr. Med. Chem. 33, 329 (2026); https://doi.org/10.2174/0109298673359029250316111019
/content/journals/cmc/10.2174/0109298673359029250316111019
/content/journals/cmc/10.2174/0109298673359029250316111019
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): immune infiltration; immunotherapy response; pan-cancer; prognostic biomarker; T lymphocytes; ZNF280A

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test